Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Ai Li

1PUBLICATIONS

13CO-AUTHORS

Predictive and prognostic markers

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (1)

Sort by Publication Date:

|Jun 26, 2020

Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trial.

Shalini Makawita, Ghassan K Abou-Alfa, Sameek Roychowdhury

Pageof 1

Frequent Collaborators

1 joint publications

Shalini Makawita

1 joint publications

Ghassan K Abou-Alfa

1 joint publications

Sameek Roychowdhury

1 joint publications

Saeed Sadeghi

1 joint publications

Ivan Borbath

1 joint publications

Lipika Goyal

1 joint publications

Angela Lamarca

1 joint publications

Do-Youn Oh

1 joint publications

Teresa Macarulla

1 joint publications

Rachna T Shroff

Frequent Collaborators

1 joint publications

Shalini Makawita

1 joint publications

Ghassan K Abou-Alfa

1 joint publications

Sameek Roychowdhury

1 joint publications

Saeed Sadeghi

Top Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on : Oct 17, 2025

See more related videos

Top Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on : Oct 17, 2025

See more related videos